Anodyne Therapy
We are eager to inform you that our outpatient clinic “Beyond Physical Therapy” now uses an exciting new technology called the Anodyne® Therapy System which has been cleared by the FDA.
If you have patients with loss of protective sensation (LOPS) due to Diabetic Peripheral Neuropathy and gait and balance abnormalities with a tendency to fall, our Peripheral Neuropathy Treatment Program can help.
Excellent clinical outcomes have been demonstrated with Diabetic Peripheral Neuropathy (DPN) including restoration of protective sensation, reduction or elimination of neuropathic and ischemic pain and resolution of chronic non-healing wounds.
We are proud to be one of very few authorized Anodyne care centers in the Knoxville area.
The Anodyne® Therapy System uses monochromatic infrared energy (MIRE) to increase local circulation and reduce pain by disassociating nitric oxide (NO) from hemoglobin. Nitric oxide is a powerful vasodilator. The localized release of NO improves nerve function and is also an important signaling molecule for the angiogenesis and collagen formation necessary for wound healing [1]. Low levels of nitric oxide and poor nitric oxide metabolism are common in patients with diabetes and are recognized to be major contributing factors in the poor microcirculation, loss of protective sensation, foot ulceration and pain of DPN [2].
Medicare issued a National Coverage Decision Memorandum[3] that acknowledges LOPS (loss of protective sensation as measured by a 5.07 Semmes Weinstein Monofilament) as the leading cause of foot ulcers and lower extremity amputations and recommends appropriate treatment for these high-risk patients.
Anodyne® is non-invasive, drug-free and safe. Best clinical results are obtained from a minimum of three treatments per week over four weeks in combination with gait and balance training followed by a home maintenance program. Anodyne® has been used on thousands of patients for more than 15 years with consistent success in treating non-healing wounds, pain and LOPS [4][5]. There are no known adverse events or drug interactions when used in accordance with manufacturer’s recommendations. The only contraindications are pregnancy and active malignancies. More information is available at http://www.anodynetherapy.com/.
[1]New England Journal of Medicine, Moncada and Higgs, Volume 329(27), Dec 30, 1993, pp. 2002-2012.
[2]Diabetes, Veves et al., Mar 1998, 47(3): 457-63.
[3] National Coverage Decision – Diabetic Peripheral Neuropathy with Loss of Protective Sensation – File: CAG-00059, Oct. 17, 2001.
[4]Advances in Wound Care, Horowitz et al., Jan/Feb 1999, 12:35-40.
[5] American Diabetes Association 61st Scientific Session, June 22-26, 2001, Abstract #: 1798-PO, Burke et al.
We are eager to inform you that our outpatient clinic “Beyond Physical Therapy” now uses an exciting new technology called the Anodyne® Therapy System which has been cleared by the FDA.
If you have patients with loss of protective sensation (LOPS) due to Diabetic Peripheral Neuropathy and gait and balance abnormalities with a tendency to fall, our Peripheral Neuropathy Treatment Program can help.
Excellent clinical outcomes have been demonstrated with Diabetic Peripheral Neuropathy (DPN) including restoration of protective sensation, reduction or elimination of neuropathic and ischemic pain and resolution of chronic non-healing wounds.
We are proud to be one of very few authorized Anodyne care centers in the Knoxville area.
The Anodyne® Therapy System uses monochromatic infrared energy (MIRE) to increase local circulation and reduce pain by disassociating nitric oxide (NO) from hemoglobin. Nitric oxide is a powerful vasodilator. The localized release of NO improves nerve function and is also an important signaling molecule for the angiogenesis and collagen formation necessary for wound healing [1]. Low levels of nitric oxide and poor nitric oxide metabolism are common in patients with diabetes and are recognized to be major contributing factors in the poor microcirculation, loss of protective sensation, foot ulceration and pain of DPN [2].
Medicare issued a National Coverage Decision Memorandum[3] that acknowledges LOPS (loss of protective sensation as measured by a 5.07 Semmes Weinstein Monofilament) as the leading cause of foot ulcers and lower extremity amputations and recommends appropriate treatment for these high-risk patients.
Anodyne® is non-invasive, drug-free and safe. Best clinical results are obtained from a minimum of three treatments per week over four weeks in combination with gait and balance training followed by a home maintenance program. Anodyne® has been used on thousands of patients for more than 15 years with consistent success in treating non-healing wounds, pain and LOPS [4][5]. There are no known adverse events or drug interactions when used in accordance with manufacturer’s recommendations. The only contraindications are pregnancy and active malignancies. More information is available at http://www.anodynetherapy.com/.
[1]New England Journal of Medicine, Moncada and Higgs, Volume 329(27), Dec 30, 1993, pp. 2002-2012.
[2]Diabetes, Veves et al., Mar 1998, 47(3): 457-63.
[3] National Coverage Decision – Diabetic Peripheral Neuropathy with Loss of Protective Sensation – File: CAG-00059, Oct. 17, 2001.
[4]Advances in Wound Care, Horowitz et al., Jan/Feb 1999, 12:35-40.
[5] American Diabetes Association 61st Scientific Session, June 22-26, 2001, Abstract #: 1798-PO, Burke et al.